Abstract
Macrophages are characterized by a marked phenotypic heterogeneity depending on their microenvironmental stimulation. Beside classical activation (M1), it has been shown that macrophages could follow a different activation pathway after stimulation with interleukin (IL)-4 or IL-13 (M2). Recently, it has been postulated that those "alternatively activated" macrophages may be critical in the control of fibrogenesis. In an experimental model of silicosis, where pulmonary macrophages play a central role, we addressed the question of whether lung fibrosis development would be associated with alternative macrophage activation. As available markers for alternative macrophage activation, type-1 arginase (Arg-1), Fizz1, Ym1/2, and mannose receptor expression were evaluated at the mRNA and/or protein levels at different stages of the disease. Nitric oxide synthase-2 (NOS-2) expression was also examined to investigate the classical counterpart. We found that the expression of Arg-1, Fizz1, and NOS-2 in adherent bronchoalveolar lavage cells was highly up-regulated 3 days after silica administration but returned to control levels during the fibrotic stage of the disease (60 days). By comparing the early response to silica in C57BL/6 and BALB/c mice, we observed that the amplitude of Arg-1 mRNA up-regulation was not associated with the severity of lung fibrosis. Using a model of manganese dioxide particles (resolutive alveolitis), we showed that this early Arg-1 mRNA was not specific to a fibrogenic lung response. Our data indicate that the modifications of M1/M2 marker expression are limited to the early inflammatory stage of silicosis and that the establishment of a fibrotic process is not necessarily associated with M2 polarization.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, Differentiation / biosynthesis
-
Antigens, Differentiation / immunology*
-
Arginase / genetics
-
Arginase / metabolism
-
Cell Differentiation / immunology*
-
Disease Models, Animal
-
Disease Progression
-
Female
-
Intercellular Signaling Peptides and Proteins
-
Interleukin-13 / immunology
-
Interleukin-4 / immunology
-
Lectins / genetics
-
Lectins / metabolism
-
Lectins, C-Type / genetics
-
Lectins, C-Type / metabolism
-
Macrophages, Alveolar / cytology
-
Macrophages, Alveolar / immunology*
-
Macrophages, Alveolar / metabolism
-
Manganese Compounds
-
Mannose Receptor
-
Mannose-Binding Lectins / genetics
-
Mannose-Binding Lectins / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Mice, Inbred C57BL
-
Nerve Growth Factor / genetics
-
Nerve Growth Factor / metabolism
-
Nitric Oxide Synthase / genetics
-
Nitric Oxide Synthase / metabolism
-
Nitric Oxide Synthase Type II
-
Oxides
-
Proteins / genetics
-
Proteins / metabolism
-
Pulmonary Fibrosis / chemically induced
-
Pulmonary Fibrosis / immunology*
-
Pulmonary Fibrosis / metabolism
-
RNA, Messenger / metabolism
-
Receptors, Cell Surface / genetics
-
Receptors, Cell Surface / metabolism
-
Silicon Dioxide
-
Silicosis / genetics
-
Silicosis / immunology*
-
Silicosis / metabolism
-
Time Factors
-
Up-Regulation / genetics
-
beta-N-Acetylhexosaminidases / genetics
-
beta-N-Acetylhexosaminidases / metabolism
Substances
-
Antigens, Differentiation
-
Intercellular Signaling Peptides and Proteins
-
Interleukin-13
-
Lectins
-
Lectins, C-Type
-
Manganese Compounds
-
Mannose Receptor
-
Mannose-Binding Lectins
-
Oxides
-
Proteins
-
RNA, Messenger
-
Receptors, Cell Surface
-
Retnla protein, mouse
-
Interleukin-4
-
Silicon Dioxide
-
Nerve Growth Factor
-
Nitric Oxide Synthase
-
Nitric Oxide Synthase Type II
-
Chil3 protein, mouse
-
beta-N-Acetylhexosaminidases
-
Arginase
-
manganese dioxide